These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 23387369)

  • 1. Development of novel genetic cancer vaccines based on membrane-attached β2 microglobulin.
    Cafri G; Margalit A; Tzehoval E; Eisenbach L; Gross G
    Ann N Y Acad Sci; 2013 Apr; 1283():87-90. PubMed ID: 23387369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of antitumor immunity by CTL epitopes genetically linked to membrane-anchored beta2-microglobulin.
    Margalit A; Sheikhet HM; Carmi Y; Berko D; Tzehoval E; Eisenbach L; Gross G
    J Immunol; 2006 Jan; 176(1):217-24. PubMed ID: 16365413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane-anchored beta 2-microglobulin stabilizes a highly receptive state of MHC class I molecules.
    Berko D; Carmi Y; Cafri G; Ben-Zaken S; Sheikhet HM; Tzehoval E; Eisenbach L; Margalit A; Gross G
    J Immunol; 2005 Feb; 174(4):2116-23. PubMed ID: 15699142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity.
    Cafri G; Sharbi-Yunger A; Tzehoval E; Alteber Z; Gross T; Vadai E; Margalit A; Gross G; Eisenbach L
    Mol Ther; 2015 Aug; 23(8):1391-1400. PubMed ID: 25997427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo.
    Agadjanyan MG; Kim JJ; Trivedi N; Wilson DM; Monzavi-Karbassi B; Morrison LD; Nottingham LK; Dentchev T; Tsai A; Dang K; Chalian AA; Maldonado MA; Williams WV; Weiner DB
    J Immunol; 1999 Mar; 162(6):3417-27. PubMed ID: 10092797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine.
    Niu BL; Du HM; Shen HP; Lian ZR; Li JZ; Lai X; Wei SD; Zou LQ; Gong JP
    Vaccine; 2012 May; 30(23):3395-404. PubMed ID: 22480929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product.
    Su Z; Vieweg J; Weizer AZ; Dahm P; Yancey D; Turaga V; Higgins J; Boczkowski D; Gilboa E; Dannull J
    Cancer Res; 2002 Sep; 62(17):5041-8. PubMed ID: 12208759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covalent linkage to beta2-microglobulin enhances the MHC stability and antigenicity of suboptimal CTL epitopes.
    Uger RA; Chan SM; Barber BH
    J Immunol; 1999 May; 162(10):6024-8. PubMed ID: 10229842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of human beta2-microglobulin on major histocompatibility complex I peptide loading and the engineering of a high affinity variant. Implications for peptide-based vaccines.
    Shields MJ; Kubota R; Hodgson W; Jacobson S; Biddison WE; Ribaudo RK
    J Biol Chem; 1998 Oct; 273(43):28010-8. PubMed ID: 9774416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
    Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant.
    Rock KL; Fleischacker C; Gamble S
    J Immunol; 1993 Feb; 150(4):1244-52. PubMed ID: 8381832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
    Speiser DE; Romero P
    Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells.
    Javorovic M; Wilde S; Zobywalski A; Noessner E; Lennerz V; Wölfel T; Schendel DJ
    J Immunother; 2008 Jan; 31(1):52-62. PubMed ID: 18157012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
    Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
    Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
    J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
    Bodey B; Bodey B; Kaiser HE
    In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.